• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

    7/23/24 3:05:41 PM ET
    $BDX
    $EMBC
    $NVO
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX).

    The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners to explore a sale.

    Embecta’s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion.

    The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nordisk A/S’s (NYSE:NVO) Ozempic, reducing demand for traditional insulin treatments for type 2 diabetes.

    Despite this, the Financial Times notes that Devdatt Kurdikar, Embecta’s CEO, remains optimistic, suggesting that the presence of GLP-1 drugs has only delayed, not eliminated, the need for insulin.

    The company’s U.S. business, which generates about half of its revenue, has been particularly affected by the shift towards GLP-1 medications.

    The FT report, citing analysts, also notes that declining profit margins and the costs associated with separating from Becton Dickinson have negatively impacted Embecta’s stock performance.

    For the fiscal year ending in September, Embecta’s adjusted net income is expected to decrease by 23% to $132 million, while annual revenues are projected to hold steady around $1.1 billion.

    Despite the current challenges, Kurdikar points to potential growth opportunities, including increasing diabetes rates in developing regions where insulin remains the preferred treatment and the potential approval of a new insulin patch pump by the FDA, which could enhance the company’s growth prospects.

    While a sale remains a possibility, the outcome is uncertain, and Embecta could continue as a listed entity.

    Price Action: EMBC stock is up 7.18% at $16.27 at last check Tuesday.

    Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

    Read Next:

    • Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study.

    Photo: Shutterstock

    Get the next $BDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDX
    $EMBC
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    Becton Dickinson and Company
    $BDX
    5/22/2025$185.00Buy → Neutral
    Citigroup
    Becton Dickinson and Company
    $BDX
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    Becton Dickinson and Company
    $BDX
    5/2/2025$192.00Buy → Neutral
    Goldman
    Becton Dickinson and Company
    $BDX
    5/2/2025Outperform → Mkt Perform
    Raymond James
    Becton Dickinson and Company
    $BDX
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Becton Dickinson and Company
    $BDX
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    Becton Dickinson and Company
    $BDX
    5/1/2025Outperform → Mkt Perform
    William Blair
    Novo Nordisk A/S
    $NVO
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $BDX
    $EMBC
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

      FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership wi

      5/28/25 6:50:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • embecta to Participate in Investor Events

      PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA. 2025 Jefferies Global Healthcare Conference Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City. 2025 Goldma

      5/27/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      FRANKLIN LAKES, N.J., May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports

      5/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    $EMBC
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Becton Dickinson downgraded by Citigroup with a new price target

      Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

      5/22/25 8:18:13 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

      5/2/25 8:06:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Goldman with a new price target

      Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

      5/2/25 8:06:36 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    $EMBC
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      5/23/25 4:35:56 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Jones Christopher Ian Montague

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:22:33 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Byington Carrie L

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      5/7/25 7:20:56 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    $EMBC
    $NVO
    Leadership Updates

    Live Leadership Updates

    See more
    • BD Names Gregory J. Hayes to Board of Directors

      FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

      3/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities

    $BDX
    $EMBC
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

      For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

      11/23/21 3:16:12 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

      For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

      7/23/21 4:06:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    $EMBC
    $NVO
    SEC Filings

    See more

    $BDX
    $EMBC
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BDX
    $EMBC
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SD filed by Embecta Corp.

      SD - Embecta Corp. (0001872789) (Filer)

      5/30/25 1:19:35 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Becton Dickinson and Company

      SD - BECTON DICKINSON & CO (0000010795) (Filer)

      5/28/25 6:05:23 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/22/25 8:55:41 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/7/24 4:21:15 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      10/25/24 5:45:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      5/23/25 4:35:56 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      2/10/25 5:03:18 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    $EMBC
    $NVO
    Financials

    Live finance-specific insights

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • BD Reports Second Quarter Fiscal 2025 Financial Results

      Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s

      5/1/25 6:30:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care